MR contrast developer Epix Pharmaceuticals reported fiscal 2004 third-quarter revenues of $3.2 million, compared to $3.9 million in the third quarter of 2003.
For the period (end-September 30), the Cambridge, MA-based firm had a net loss of $6.4 million, compared with a net loss of $3.4 million reported for the same period last year.
By AuntMinnie.com staff writers
October 27, 2004
Related Reading
Epix Medical changes name, September 8, 2004
Epix begins testing blood clot imaging agent, August 6, 2004
Epix names Uprichard president and COO, July 16, 2004
Epix testing MS-325 for cardiac imaging, July 12, 2004
Epix launches new MS-325 trial, July 8, 2004
Copyright © 2004 AuntMinnie.com
